1. Home
  2. TACT vs SCYX Comparison

TACT vs SCYX Comparison

Compare TACT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$3.48

Market Cap

37.2M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.86

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
SCYX
Founded
1996
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.2M
32.6M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
TACT
SCYX
Price
$3.48
$0.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$3.00
AVG Volume (30 Days)
41.5K
328.6K
Earning Date
06-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
87.88
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
$21.67
$90.24
Revenue Next Year
$7.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.57
52 Week High
$5.70
$1.29

Technical Indicators

Market Signals
Indicator
TACT
SCYX
Relative Strength Index (RSI) 44.89 62.21
Support Level N/A $0.69
Resistance Level $3.87 $0.88
Average True Range (ATR) 0.22 0.06
MACD -0.00 0.01
Stochastic Oscillator 50.72 72.97

Price Performance

Historical Comparison
TACT
SCYX

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: